⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Curocell Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Curocell Inc.
↗Daejeon, South Korea
Curocell is a clinical-stage biotechnology company headquartered in Daejeon, South Korea, focused on the development of next-generation CAR-T cell therapies. The company utilizes its proprietary OVIS™ (Overcome Immune Suppression) platform technology, which is designed to modulate PD-1 and TIGIT immune-suppressive signaling to enhance T-cell persistence and anti-tumor activity in both hematologic malignancies and solid tumors.
In April 2026, Curocell achieved a significant milestone with the regulatory approval of RIMQARTO® (anbalcabtagene autoleucel), Korea's first domestically developed CAR-T therapy, indicated for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). The company operates its own GMP manufacturing facility to ensure rapid supply and quality control.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$82.4M
Investors:Atinum Investment, Yukyung PSG Asset Management, Seoul Investment Partners
STOCK
Exchange:KOSDAQ
Ticker:372320
Market Cap:$0.45B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Cell therapy, CAR-T
Active Trials:0
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:ProBio (CDMO partner for BLA and commercial production)
COMPETITION
Position:Emerging
Competitors:MaaT Pharma, Ossium Health, Adicet Bio, Autolus
LEADERSHIP
Key Executives:
Gunsoo Kim - CEO
Scientific Founders:Gunsoo Kim, Chan Hyuk Kim, Hyunbo Shim
LINKS
Website:curocellbtx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Curocell Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.